Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Novartis Pharmaceuticals Corporation
Description:
Over 73 million adults in the United States have
hypercholesterolemia and are at elevated risk for atherosclerotic
cardiovascular disease. Low-density lipoprotein cholesterol (LDL-C)
is a primary mediator of the development of heart disease and plays
a key role in determining cardiovascular risk and overall health
management. Early and aggressive lowering of LDL-C reduces the risk
of atherosclerotic cardiovascular disease (ASCVD) events in patients
with hypercholesterolemia, and every 1.0 mmol/L reduction in LDL-C
is estimated to lead to ~20% reduction in the relative risk of major
cardiovascular events. Statins are the mainstay of
hypercholesterolemia management, but many patients do not tolerate
statin-based treatment, which ultimately leads to medication
nonadherence, ASCVD events, and higher healthcare costs. On the
other hand, some patients, including those with pre-existing ASCVD
or severe hypercholesterolemia, do not reach recommended LDL-C
treatment targets despite intensive statin therapy. Non-statin
agents can be useful for patients who inadequately respond to or are
intolerant of statin therapy. Fortunately for patients with high LDL-C,
several new treatments have recently become available as an adjunct
or instead of statin therapies. These options, including agents that
inhibit production of PCSK9, have shown improved efficacy and
safety, offering patients the potential for improved outcomes and
quality of life. With so many new options becoming available in
recent years that have shown the ability to lower LDL-C and reduce
cardiovascular risk in lipid management, it is critical that
physician medical directors, payers, cardiologists, pharmacy
directors, pharmacists, nurse case managers, and other HCPs are
updated on the comparisons among safety, efficacy, and
administration data on these options, possible strategies for
implementing them into the treatment paradigm, and key points that
managed care professionals need to know, which will ultimately
improve both clinical and economic outcomes.
Upon completion of this
activity, participants will be able to:
-
Assess the clinical and economic
consequences of patient non-adherence and clinical inertia on
ASCVD event risk in patients with hypercholesterolemia
-
Recognize the need for the early and
adequate intensification of LDL-C lowering therapy beyond
statins to address ASCVD risk
-
Examine the clinical data and
guideline recommendations for the use of PCSK9-modulating
therapies in the treatment of hypercholesterolemia
-
Explore the role of siRNA-based
inhibition of PCSK9 in managing patients with
hypercholesterolemia or ASCVD
-
Identify patients who may benefit
from PCSK9 inhibition in place of or as an adjunct to statin
therapy
-
Implement managed care strategies to
integrate evidence-based use of PCSK9-modulating therapies while
controlling healthcare resource utilization
|
Faculty: |
Robert S. Rosenson, MD
Professor of Cardiology and Director of Metabolism and
Lipids
Icahn School of Medicine at Mount Sinai |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Rosenson has served as a consultant for Amgen,
CRISPER, Eli Lilly, Lipigon, Novartis, Precision
Biosciences, Regeneron, UltraGenyx, and Verve. He has
served as a speaker for Kowa. He has received
grant/research support from Amgen, Arrowhead, Eli Lilly,
Novartis, and Regeneron. He holds stock in MedImergent,
LLC. His presentation has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |